SCHEMBL2473034

SCHEMBL2473034

ClCCOCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.64
NAAA Q02083 1/20 0.47
IDO1 P14902 1/20 0.46
AGXT P21549 1/20 0.44
LTA4H P09960 1/20 0.44
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CA1 P00915 3/20 0.42
CA2 P00918 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HRH4 Q9H3N8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
TACR1 P25103 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5726273 0.96 TSHR (0.58) TSHRNAAAIDO1AGXTLTA4H
SCHEMBL6267162 0.96 TSHR (0.58) TSHRNAAAIDO1AGXTLTA4H
SCHEMBL5848836 0.92 TSHR (0.54) TSHRNAAAIDO1AGXTLTA4H
SCHEMBL14673871 0.89 TSHR (0.56) TSHRNAAAIDO1AGXTLTA4H
SCHEMBL9671825 0.87 TSHR (0.43) TSHRNAAAIDO1AGXTLTA4H
SCHEMBL1001167 0.86 TSHR (0.58) TSHRNAAAIDO1AGXTLTA4H
SCHEMBL1991359 0.85 TSHR (0.78) TSHRNAAAIDO1AGXTLTA4H
SCHEMBL3488296 0.85 TSHR (0.56) TSHRNAAAIDO1LTA4HTDP1
SCHEMBL8998380 0.85 TSHR (0.56) TSHRNAAAIDO1AGXTLTA4H
SCHEMBL344059 0.84 TSHR (0.61) TSHRNAAAIDO1AGXTLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0777661-A1 NATRIURETIC AND ANTI-HYPERTENSIVE COMPOUNDS LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 1997-06-11 EP claimed
WO-1996002522-A1 NATRIURETIC AND ANTI-HYPERTENSIVE COMPOUNDS LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 1996-02-01 WO claimed
WO-2025229046-A1 SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) 2025-11-06 WO disclosed
EP-4644375-A1 SUBSTITUTED HYDROQUINOLINES FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME Molius Saglik Teknolojileri Anonim Sirketi (TR) 2025-11-05 EP disclosed
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2023-12-05 US disclosed
CN-109134802-B Phosphorus-containing halogen-free flame-retardant thermoplastic polyurethane elastomer composition and preparation method and application thereof 万华化学集团股份有限公司 2023-09-19 CN disclosed
EP-3700911-B1 NOVEL MACROCYCLIC DERIVATIVES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2023-09-06 EP disclosed
CN-112334441-B Polymerizable polar compound, liquid crystal composition, and liquid crystal display element 捷恩智株式会社 2023-08-01 CN disclosed
CN-111511750-B Macrocyclic derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2023-06-13 CN disclosed
US-11631897-B2 Ionic liquid additive for lithium-ion battery HIGH TECH BATTERY INC. (TW) 2023-04-18 US disclosed
US-11626620-B2 Ionic liquid additive for lithium-ion battery HIGH TECH BATTERY INC. (TW) 2023-04-11 US disclosed
US-5846967-A Natriuretic and anti-hypertensive compounds LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 1998-12-08 US disclosed
CN-1172108-A Triazole derivative or salt thereof SS PHARMACEUTICAL CO (JP) 1998-02-04 CN disclosed
EP-0814079-A1 Triazole derivative or salt thereof SS PHARMACEUTICAL CO., LTD. (JP) 1997-12-29 EP disclosed
EP-0777661-A1 NATRIURETIC AND ANTI-HYPERTENSIVE COMPOUNDS LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 1997-06-11 EP disclosed
WO-1996002522-A1 NATRIURETIC AND ANTI-HYPERTENSIVE COMPOUNDS LOMA LINDA UNIVERSITY MEDICAL CENTER (US) 1996-02-01 WO disclosed
US-5102667-A Antiallergens, antiinflammatory agents, nervous system disorders, immunology, psychological disorders RHONE-POULENC SANTE (FR) 1992-04-07 US disclosed
US-4835312-A Production process of N-substituted amide compounds MITSUI CHEMICALS, INCORPORATED (JP) 1989-05-30 US disclosed
US-4647565-A 2-(2-quinazolinylaminoalkoxymethyl)-1,4-dihydropyridine derivatives as cardiovascular agents PFIZER INC. (US) 1987-03-03 US disclosed
EP-0168151-A1 Dihydropyridine cardiovascular agents Pfizer Limited (GB) 1986-01-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11833162-B2 Macrocyclic derivatives, process for preparing same and pharmaceutical compositions containing same C1R, F12, RDX TSHR 493/4885NAAA 3561/4885IDO1 3955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.